Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome

Annals of Hematology

Volumn 88, Issue 7, 2009, Pages 639-645

  Choi, Kyung A ^a   Lee, Jung Eun ^a   Kim, Yoon Goo ^a   Kim, Dae Joong ^a   Kim, Kihyun ^a   Ko, Young Hyeh ^a   Oh, Ha Young ^a   Kim, Won Seog ^a   Huh, Wooseong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Burkitt leukemia; Burkitt lymphoma; Continuous venovenous hemofiltration (CVVH); Hyperuricemia; Tumor lysis syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; HYDROCORTISONE; METHOTREXATE; PREDNISONE; VINCRISTINE SULFATE;

ADULT; ARTICLE; BURKITT LEUKEMIA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; LEUKEMIA; MALE; OVERALL SURVIVAL; PERONEUS NERVE PARALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR LYSIS SYNDROME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMOFILTRATION; HUMANS; HYDROCORTISONE; HYPERURICEMIA; KIDNEY FUNCTION TESTS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; TUMOR LYSIS SYNDROME; VINCRISTINE;

EID: 67349167005     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0642-1     Document Type: Article

References (27)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994 doi: 10.1056/NEJM199309303291402
2. Blum KA, Lozanski G, Byrd JC (2004) Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020 doi: 10.1182/blood-2004-02-0405
3. Kasamon YL, Swinnen LJ (2004) Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol 16:429-435 doi: 10.1097/ 00001622-200409000-00003
4. Hande KR, Garrow GC (1993) Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94:133-139 doi: 10.1016/ 0002-9343(93)90174-N
5. Hsu HH, Chan YL, Huang CC (2004) Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: Clinical features and therapeutic approach. J Nephrol 17:50-56
6. Gasparini M, Rottoli L, Massimino M, Gianni MC, Ballerini E, Ravagnani F et al (1993) Curability of advanced Burkitt's lymphoma in children by intensive short-term chemotherapy. Eur J Cancer 29A:692-698 doi: 10.1016/ S0959-8049(05)80348-X
7. Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N et al (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664-674
8. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C et al (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87:495-508
9. Saccente SL, Kohaut EC, Berkow RL (1995) Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol 9:569-573 doi: 10.1007/BF00860936
10. Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339
11. Cairo MS, Bishop M (2004) Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol 127:3-11 doi: 10.1111/ j.1365-2141.2004.05094.x
12. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphaël M, Terrier-Lacombe MJ, Société Française d'Oncologie Pédiatrique (2001) The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370-3379 doi: 10.1182/blood.V97.11.3370
13. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL et al (2004) Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia Group B Study 9251. Cancer 100:1438-1448 doi: 10.1002/cncr.20143
14. Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D et al (2004) Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leuk Lymphoma 45:761-767 doi: 10.1080/1042819031000141301
15. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, Guarnaccia C, Lewis MS, McKendrick J, Stenning SP, Wright D, UKLG LY06 collaborators (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264-1274 doi: 10.1093/ annonc/mdf253
16. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M et al (2001) Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B Study 9251. J Clin Oncol 19:4014-4022
17. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M et al (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470
18. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS (2005) Burkitt lymphoma in adults: A prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 16:1928-1935 doi: 10.1093/annonc/mdi403
19. Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H et al (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 44:77-83 doi: 10.1080/1042819021000054661
20. Stapleton FB, Strother DR, Roy S III, Wyatt RJ, McKay CP, Murphy SB (1988) Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 82:863-869
21. Tan HK, Bellomo R, M'Pis DA, Ronco C (2001) Phosphatemic control during acute renal failure: Intermittent hemodialysis versus continuous hemodiafiltration. Int J Artif Organs 24:186-191
22. Yim BT, Sims-McCallum RP, Chong PH (2003) Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 37:1047-1054 doi: 10.1345/aph.1C336
23. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D (2008) Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 80:331-336 doi: 10.1111/j.1600-0609.2007.01013.x
24. Sood AR, Burry LD, Cheng DK (2007) Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy 27:111-121 doi: 10.1592/ phco.27.1.111
25. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998-3003 doi: 10.1182/blood.V97.10.2998
26. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S et al (2005) Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial. Leukemia 19:34-38
27. Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K et al (2006) Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 37:997-1001 doi: 10.1038/sj.bmt.1705379